Development, Optimization and Absorption Mechanism of DHP107, Oral Paclitaxel Formulation for Single-Agent Anticancer Therapy
- Development, Optimization and Absorption Mechanism of DHP107, Oral Paclitaxel Formulation for Single-Agent Anticancer Therapy
- 이인현; 홍정완; 장유라; 박영택; 정혜선
- paclitaxel; oral anticancer drug; single-agent; stomach cancer
- Issue Date
- New advances in The basic and clinical gastroenterology
- , 357-374
- In conclusion, we prepared oral paclitaxel formulations that do not contain P-glycoprotein
inhibitors as active pharmaceutical ingredients. The formulations are liquid at body
temperature and can solubilize paclitaxel effectively. The oral bioavailability of paclitaxel
was 14 ~ 20 % when compared to the intravenous Taxol formulation without concomitant
administration of P-glycoprotein inhibitors. Preclinical efficacy study on mice showed that
the tumor size was reduced significantly for the human non-small cell lung carcinoma. In
separate studies, we have determined the tissue distribution of paclitaxel after oral
administration (manuscript in preparation) and performed pre-clinical antitumor efficacy
studies in mice with several tumor types (manuscript in preparation). Regulatory preclinical
experiments to initiate the clinical evaluations of DHP107 have also been carried out.
- Appears in Collections:
- KIST Publication > ETC
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.